Study of Dietary Intervention Under 100 mmol in Heart Failure - SODIUM-HF
Contribution To Literature:
The SODIUM-HF trial failed to show that a low-sodium diet prevented adverse cardiovascular events.
The goal of the trial was to evaluate a low-sodium diet compared with usual care among ambulatory patients with heart failure.
Patients with New York Heart Association (NYHA) class II-III heart failure symptoms on optimal medical therapy were randomized to a low-sodium diet (<1500 mg daily) (n = 397) versus usual care (n = 409).
- Total number of enrollees: 806
- Duration of follow-up: 12 months
- Mean patient age: 66 years
- Percentage female: 32%
- Percentage with diabetes: 33%
- Patients ≥18 years of age with heart failure (preserved or reduced left ventricular systolic function)
- NYHA class II-III symptoms
- End-stage renal disease on hemodialysis
- Uncontrolled thyroid or end-stage liver failure
- Cardiac device or revascularization in the previous month or planned in the next 3 months
- Hospitalization for cardiovascular cause in the last month
- Uncontrolled atrial fibrillation
- Active malignancy with expected life span <2 years
- Poor compliance with the study protocol
- Enrollment in another study
- Average daily sodium intake <1500 mg
- Serum sodium <130 mmol/L
Other salient features/characteristics:
- Mean ejection fraction: 36%
- Atrial fibrillation: 39%
- At 12 months, dietary sodium intake was 1658 mg in the low-sodium diet group vs. 2073 mg in the usual care group (p < 0.0001).
The trial was terminated early due to impact from the COVID-19 pandemic.
The primary outcome, all-cause mortality, or cardiovascular emergency department visit/hospitalization at 12 months, occurred in 15% of the low-sodium group vs. 17% of the usual care group (hazard ratio [HR] 0.89, p = 0.53).
- All-cause mortality at 12 months: 6% of the low-sodium group vs. 4% of the usual care group (HR 1.38, p = 0.32)
- The difference in the adjusted mean Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score at 12 months was 3.38 points greater in the low-sodium group vs. usual care group (p = 0.011).
- The difference in the adjusted mean 6-minute walk test at 12 months was 6.6 minutes greater in the low-sodium group vs. usual care group (p = 0.41).
Among ambulatory patients with heart failure, a low-sodium diet was not associated with a reduction in adverse cardiovascular events. A low-sodium diet was associated with a modest improvement in quality of life; however, 6-minute walk test was not different between treatment groups. Unfortunately, the trial was terminated early, limiting interpretation of the findings.
Ezekowitz JA, Colin-Ramirez E, Ross H, et al., on behalf of the SODIUM-HF Investigators. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomized, controlled trial. Lancet 2022;399:1391-1400.
Presented by Dr. Justin A. Ezekowitz at the American College of Cardiology Annual Scientific Session (ACC 2022), Washington, DC, April 2, 2022.
Clinical Topics: Arrhythmias and Clinical EP, COVID-19 Hub, Diabetes and Cardiometabolic Disease, Heart Failure and Cardiomyopathies, Prevention, Implantable Devices, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Acute Heart Failure, Diet
Keywords: ACC22, ACC Annual Scientific Session, Atrial Fibrillation, Cardiomyopathies, COVID-19, Defibrillators, Implantable, Diet, Sodium-Restricted, Emergency Service, Hospital, Heart Failure, Kidney Failure, Chronic, Liver Failure, Neoplasms, Quality of Life, Renal Dialysis, Secondary Prevention, Sodium, Sodium, Dietary, Stroke Volume
< Back to Listings